-
Xenograft model
-
In vivo target inhibition model
Jubilant Biosys provides state-of-the-art preclinical
xenograft models with multiple cell lines to support
preclinical research and assessment of anticancer drugs.
Our expert scientific staffs possess strong industrial and
academic backgrounds. With our new and complete laboratory
facilities, validated xenograft models and supporting
studies, Jubilant Biosys is able to support a complete
discovery and development program for anti-cancer drugs.
We have established multiple in vitro and in vivo assay
systems to evaluate novel anti-cancer compounds. Each
assay is designed to understand specific aspects of drug
property and its mechanism of action. By accessing our
comprehensive capability, our customers can advance
development programs in a timely and cost-effective
manner. Jubilant Biosys scientists have extensive
experience with the design and execution of efficacy
studies for all types of experimental cancer therapeutic
agents including both small molecules and biologics. Our
current cancer pharmacology service portfolio includes-
Human Xenograft Model
Human xenograft models are generated by inoculating a
tumour cell lines into an immunodeficient rodent such as
nude mice. This is a subcutaneous xenograft models. This
model involves implantation of tumour cells via
subcutaneous injection into the flank of nude mice. This
model provides consistent and reproducible cell growth and
permits easy access to the tumour for treatment and
calliper measurement. We offer traditional subcutaneous
models and other models and can customize models to meet a
sponsor’s needs.
Human Tumour Cell lines available at Jubilant Biosys are as
follows-
|
Breast
Cancer |
MCF-7, MDA-MB231 |
|
Prostate
cancer |
PC-3, LNCap |
|
Colorectal
cancer |
HCT-116, COL205, CACO2, HT-29, SW480, SW620 |
|
Liver
Cancer |
HepG2 |
|
Lung
cancer |
Calu 6, A549 |
|
Ovarian
cancer |
SK-OV-3 |
|
Fibro
sarcoma |
HT-1080 |
|
Gastric
cancer |
NCI-N87, BGC823, MGC803 |
|
Vulvar/epitheloid
cancer |
A431 |
|
Melanoma |
A375 |
|
Pancreatic
cancer |
Panc-01 |
|
Kidney
cancer |
A498, Caki-2 |
|
Leukemia |
K562 |
|
Myeloma |
8226 |
Typical Study Parameters
we evaluate at Jubilant Biosys
- Human tumour cells grown in
culture (ATCC or custom lines)
- Cell implant subcutaneously
into immuno-compromised animals
- Tumours measured during
growth phase
- Animals treated with
vehicle, test article, and positive controls
- Various protocol-specified
parameters/markers assessed ex vivo or in vivo assays
- Report preparation.
Jubilant Biosys scientific
teams not only investigate the effect of test article on
tumour growth but also actively participate in investigating
the mode of action. In PK/PD studies the tumours are excised
from the test article treated mice group along with
respective control groups. Then the effect of test article
at molecular level is investigated in different cell based
assays. The MTD of the compound is also analysed.
|
